Form 4: Fennec CFO Robert Andrade Acquires Shares
Insider Transaction Report
Fennec Pharmaceuticals' CFO, Robert Andrade, acquired 2,430 common shares through the release of restricted stock.
Summary
- Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals Inc. (FENC), acquired 2,430 common shares.
- The transaction occurred on October 31, 2025, and represents shares released from restriction.
- These shares were originally awarded on March 31, 2023, and May 16, 2024.
- Following this transaction, Andrade directly beneficially owns a total of 173,104 common shares.
Sentiment
Score: 7
Explanation: The acquisition of shares by the CFO, albeit through restricted stock release, generally signals alignment of management's interests with shareholders, which is a positive indicator. However, it is a routine compensation event rather than a discretionary market purchase.
Positives
- Increased direct beneficial ownership by a key executive, which generally aligns management's interests with those of shareholders.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This Form 4 filing details a routine insider transaction related to executive compensation, which does not directly reflect broader industry trends but is a standard disclosure for publicly traded companies.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The increase in direct beneficial ownership by the CFO may be viewed positively as it enhances alignment between management and shareholder interests.
- Employees: This transaction reflects standard executive compensation practices, which can be a factor in employee retention and motivation at the leadership level.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of initial share award from which some shares were released from restriction. |
| 05/16/2024 | Date of initial share award from which some shares were released from restriction. |
| 10/31/2025 | Date of transaction where 2,430 common shares were acquired through release from restriction. |
| 11/03/2025 | Date the Form 4 filing was signed by Robert Andrade. |
Keywords
Fennec Pharmaceuticals, FENC, Robert Andrade, CFO, Insider Transaction, Restricted Stock, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.